Business Context and Reporting Period
This Form 8-K was filed by Aquinox Pharmaceuticals, Inc. on March 16, 2015. The filing serves to announce the company's financial results for the fiscal year ended December 31, 2014. The full details of these results are contained in a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the issuance of results for the year ended December 31, 2014.
Guidance, Outlook, and Risks
The filing does not include specific guidance, outlook, management commentary, or risk factors within the main body text. It explicitly states that the information is furnished but not "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the attached Exhibit 99.1 Press Release, as they are absent from this summary text.
- Confirm the company name is Aquinox Pharmaceuticals, Inc. (Note: The request metadata listed "Neurogene Inc.", but the filing clearly identifies Aquinox).
- Review the press release for any updates on clinical trials or product development, which are typical for this sector but not detailed in the 8-K text.
- Check the company's liquidity status in the full financial statements to assess runway for operations.